TRVN:OTCMKTS
Trevena Inc
0,066 US$
0,00%
(0,00) 1 d
12 oct, 14:57:26 GMT-4 · USD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de TRVN...
Cap. burs.
57,01 mil
Vol. medio
210,00
Volumen
16,00
Máximo en 52 sem.
1,50 US$
Mínimo en 52 sem.
0,00 US$
Beta
1,07
Acciones en circulación
864,00 mil
N.º de empleados
23
Cap. burs.
57,01 mil
Vol. medio
210,00
Volumen
16,00
Máximo en 52 sem.
1,50 US$
Mínimo en 52 sem.
0,00 US$
Beta
1,07
Acciones en circulación
864,00 mil
N.º de empleados
23
Noticias
De fuentes web y partners de noticias
ad-hoc-news.de
·
hace 1 día
MarketBeat estimates results for Trevena stock
Perfil
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Acerca de Trevena Inc